PGRMC1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL4699731	1.00	2/20
SCHEMBL16111548	1.00	2/20
SCHEMBL4697866	0.89	2/20
SCHEMBL4697696	0.86	2/20
SCHEMBL23092285	0.86	2/20
SCHEMBL22024695	0.86	2/20
SCHEMBL16136600	0.84	2/20
SCHEMBL4699947	0.83	2/20
SCHEMBL22025026	0.82	2/20
SCHEMBL22119546	0.82	2/20
SCHEMBL18804561	0.81	2/20
SCHEMBL22024561	0.81	2/20
SCHEMBL22025030	0.81	2/20
SCHEMBL24532038	0.81	2/20
SCHEMBL22024567	0.81	2/20
SCHEMBL4699140	0.80	2/20
SCHEMBL4922941	0.80	2/20
SCHEMBL22025313	0.80	2/20
SCHEMBL22025316	0.80	2/20
SCHEMBL23092250	0.80	2/20

Clinical trials — most relevant to PGRMC1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
How DHEA Supplements Affect Coagulation in Women Using Birth Control Pills	PHASE4	COMPLETED
Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification	PHASE2/PHASE3	RECRUITING
Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Breast Cancer	PHASE3	COMPLETED
A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer	PHASE2	UNKNOWN
Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy	PHASE2	ACTIVE_NOT_RECRUITING
Study of Physiological and High Dose Estradiol in the Treatment of Hormone Receptor Positive Metastatic Breast Cancer	PHASE2	COMPLETED
A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.	PHASE2	UNKNOWN
A Phase II Study of Therapy With Paclitaxel, Carboplatin and Megesterol Acetate for the Management of Uterine Cancer	PHASE2	COMPLETED
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer	PHASE2	COMPLETED
Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer	PHASE2	WITHDRAWN
Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy	PHASE2	ACTIVE_NOT_RECRUITING
A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer	PHASE2	COMPLETED
Faslodex 500mg Multiple Dose Tolerability Study in BC Patients	PHASE1	COMPLETED
PRECAMA: Molecular Subtypes of Premenopausal Breast Cancer in Latin American Women	nan	RECRUITING
Clinical and Basic Research on the Necessity of Scar Tissue Resection During Intrauterine Adhesions	nan	UNKNOWN
Real-World Data of Clinicopathological Characteristics and Management of Breast Cancer Patients According to HER2 Status	nan	COMPLETED
FES-PET for Patients Treated on NCI Protocol 8762	nan	WITHDRAWN
Expression of Steroid Receptors in Endometrium	nan	COMPLETED
Uterine Cavity Assessment and Endometrial Hormonal Receptors in Women With Peri and Post Menopausal Bleeding	nan	COMPLETED
A Randomized Controlled Study on the Effect of MRJPs on Improving Ovarian Function and Endometrial Receptivity	nan	RECRUITING
Fractional / Pixel CO2 Laser Treatment of Vulvar Atrophy and Lichen Sclerosus	nan	COMPLETED
Association of Tumour Grade and Sex Steroid Receptor as a Prognostic Index in Breast Cancer	nan	UNKNOWN
Study of Tissue Samples From Women Treated With Paclitaxel for Breast Cancer on Clinical Trial CALGB-9344 or CALGB-9741	nan	COMPLETED
The Effect of Progesterone on Human Endometrium	nan	COMPLETED
Uterine Cavity Assessment and Endometrial Gene Expression in Tamoxifen Treated Breast Cancer Patients	nan	UNKNOWN
Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy	nan	RECRUITING
ERA Test in Patients With Recurrent Implantation Failure	nan	UNKNOWN
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
Quality Of Life While Receiving Faslodex	nan	COMPLETED
Clinical Cohort Study on the Endocrinology and Vaginal/Endometrial Microbiome of the Luteal Phase in Assisted Reproduction	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a PGRMC1 binder may also engage these)

Protein	Name	Similarity
P70580	—	1.000	P70580 →
Q5RED0	—	1.000	Q5RED0 →
Q95250	—	1.000	Q95250 →
Q17QC0	—	0.999	Q17QC0 →
O55022	—	0.999	O55022 →
Q5ZKN2	—	0.990	Q5ZKN2 →
PGRMC2	Membrane-associated progesterone receptor component 2	0.978	landscape →
Q6IUR5	—	0.975	Q6IUR5 →
Q1JQA5	—	0.974	Q1JQA5 →
P16081	—	0.970	P16081 →
EEF1B2	Elongation factor 1-beta	0.970	landscape →
B4HMY3	—	0.969	B4HMY3 →
Q9YGQ1	—	0.968	Q9YGQ1 →
B3NML0	—	0.968	B3NML0 →
B4LNA1	—	0.968	B4LNA1 →
EIF3C	Eukaryotic translation initiation factor 3 subunit C	0.968	landscape →
Q5E983	—	0.968	Q5E983 →
B5ME19	—	0.968	B5ME19 →
B4P562	—	0.968	B4P562 →
P27967	—	0.968	P27967 →
Q3SYW6	—	0.968	Q3SYW6 →
Q9UMX5	—	0.967	Q9UMX5 →
B4KN00	—	0.967	B4KN00 →
B3MIF1	—	0.967	B3MIF1 →
Q6DET9	—	0.967	Q6DET9 →
A2CES0	—	0.967	A2CES0 →
A2YQ56	—	0.967	A2YQ56 →
Q28Z41	—	0.967	Q28Z41 →
Q2NL17	—	0.966	Q2NL17 →
P29412	—	0.966	P29412 →